<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">docru</journal-id><journal-title-group><journal-title xml:lang="ru">Доктор.Ру</journal-title><trans-title-group xml:lang="en"><trans-title>Title</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-2378</issn><issn pub-type="epub">2713-2994</issn><publisher><publisher-name>ООО "ГК "РУСМЕДИКАЛ"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31550/1727-2378-2024-23-8-23-31</article-id><article-id custom-type="elpub" pub-id-type="custom">docru-218</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Предикторы неблагоприятного прогноза у больных ишемической болезнью сердца, перенесших коронарное шунтирование</article-title><trans-title-group xml:lang="en"><trans-title>Predictors of Unfavorable Prognosis in Patients with Coronary Heart  Disease Who Have Undergone Coronary Artery Bypass Grafting</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2889-0706</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колодина</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolodina</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Колодина Диана Александровна — ассистент кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой имени академика Г.Ф. Ланга</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><email xlink:type="simple">diana.kolodina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5349-2227</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беляева</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyaeva</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беляева Ольга Дмитриевна. — д. м. н., доцент, профессор кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой имени академика Г.Ф. Ланга</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><email xlink:type="simple">olgad.bel@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5358-5968</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беркович</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Berkovich</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беркович Ольга Александровна — профессор кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой имени академика Г.Ф. Ланга, д. м. н., профессор</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><email xlink:type="simple">oberkovich@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2025</year></pub-date><volume>23</volume><issue>8</issue><issue-title>КАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНА</issue-title><fpage>23</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Колодина Д.А., Беляева О.Д., Беркович О.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Колодина Д.А., Беляева О.Д., Беркович О.А.</copyright-holder><copyright-holder xml:lang="en">Kolodina D.A., Belyaeva O.D., Berkovich O.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://docru.elpub.ru/jour/article/view/218">https://docru.elpub.ru/jour/article/view/218</self-uri><abstract><sec><title>Цель</title><p>Цель. Выявить предикторы неблагоприятного течения ишемической болезни сердца (ИБС) у больных, перенесших коронарное шунтирование (КШ).</p></sec><sec><title>Дизайн</title><p>Дизайн. Проспективное наблюдение.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В проспективное наблюдение продолжительностью 24 месяца для выявления предикторов неблагоприятного течения ИБС включены 98 больных, перенесших КШ. Медиана возраста — 63 (56; 68) года. Определяли концентрацию глюкозы плазмы крови, показатели липидного спектра, инсулина, мочевой кислоты, белка, связывающего жирные кислоты 4 (FABP4), в сыворотке крови, индекс инсулинорезистентности, уровень экспрессии микроРНК-21 в плазме крови и миокарде, относительный уровень матричной РНК (мРНК) гена FABP4 в эпикардиальной и подкожной жировой ткани. За комбинированную конечную точку (ККТ) принимали развитие стенокардии напряжения, инфаркта миокарда (ИМ), тромбоза шунта/функционально значимого рестеноза шунта, нарастание дисфункции миокарда, острое нарушение мозгового кровообращения по ишемическому типу, летальный исход.</p></sec><sec><title>Результаты</title><p>Результаты. В течение 24 месяцев у 15 (15,3%) больных (11 мужчин (73,3%) и 4 (26,7%) женщин) с ИБС, перенесших КШ, наступила ККТ. Медиана времени наблюдения до возникновения ККТ составила 11,1 (10,5; 11,9) месяца. Семь пациентов умерли, у 3 зафиксирован тромбоз шунта, у 4 — гемодинамически значимый стеноз артерии, ранее не подвергшейся шунтированию/стентированию (выполнено чрескожное коронарное вмешательство), у 1 — острое нарушение мозгового кровообращения по ишемическому типу. Риск наступления ККТ у больных ИБС, перенесших КШ, определялся такими факторами, как сахарный диабет (СД) 2 типа, наличие зон нарушения локальной сократимости миокарда, а риск возникновения самой «жесткой» конечной точки — летального исхода — в дополнение к этим факторам ассоциировался с ожирением, гиперурикемией, дебютом ИБС с ИМ и увеличением уровня FABP4 в сыворотке крови. Повышение концентрации FABP4 в сыворотке крови значительно увеличивает риск летального исхода.</p></sec><sec><title>Заключение</title><p>Заключение. У больных ИБС, перенесших КШ, наиболее значимыми факторами, определяющими наступление ККТ в течение первых 24 месяцев, являются СД 2 типа и наличие зон нарушения локальной сократимости миокарда, которые, наряду с ожирением, гиперурикемией, указанием в анамнезе на дебют ИБС с ИМ и повышением уровня FABP4 в сыворотке крови, ассоциируются с увеличением риска летального исхода.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To identify predictors of unfavorable course of coronary artery disease (CAD) in patients who underwent coronary artery bypass grafting (CABG).</p></sec><sec><title>Design</title><p>Design. Prospective observation.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A prospective observation of 24 months to identify predictors of unfavorable course of CAD included 98 patients who underwent CABG. Median age — 63 (56; 68) years. The concentration of blood plasma glucose, lipid parameters, insulin, uric acid, fatty acid binding protein 4 (FABP4) in the blood serum, the insulin resistance index, the level of expression of microRNA-21 in the blood plasma and myocardium, relative level of messenger RNA FABP4 gene in epicardial and subcutaneous adipose tissue were determined. The development of angina pectoris, myocardial infarction (MI), bypass thrombosis/functionally significant bypass restenosis, increase in myocardial dysfunction, acute ischemic cerebrovascular accident, and death were taken as the major adverse cardiac events (MACE).</p></sec><sec><title>Results</title><p>Results. Over the course of 24 months, 15 (15.3%) patients (11 men (73.3%) and 4 (26.7%) women) with CAD who underwent CABG achieved the MACE. The median follow-up time before the occurrence of MACE was 11.1 (10.5; 11.9) months. Among all MACE, 7 patients had a fatal outcome, 3 had shunt thrombosis, 4 had hemodynamically significant stenosis of an artery that had not previously undergone bypass/stenting and underwent percutaneous coronary intervention, 1 had an acute ischemic cerebrovascular accident. The risk of the onset of MACE in patients with CAD who underwent CABG was determined by such factors as type 2 diabetes mellitus, the presence of zones of impaired local myocardial contractility, and the risk of the most “hard” end point — death, in addition to these factors was associated with obesity, hyperuricemia, with the onset of CAD with MI and an increase in the level of FABP4 in the blood serum. Increasing serum FABP4 levels significantly reduces the risk of death.</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with CAD who have undergone CABG, the most significant factors determining the onset of MACE during the first 24 months are type 2 diabetes mellitus and the presence of zones of impaired local myocardial contractility, which, along with such factors as obesity, hyperuricemia, and a history indicating the onset of CAD with MI and an increase in serum FABP4 levels are associated with an increased risk of death.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>белок</kwd><kwd>связывающий жирные кислоты 4</kwd><kwd>ген FABP4</kwd><kwd>подкожная жировая ткань</kwd><kwd>эпикардиальная жировая ткань</kwd><kwd>микроРНК-21</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>коронарное шунтирование</kwd><kwd>гиперурикемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>fatty acid binding protein 4</kwd><kwd>FABP4 gene</kwd><kwd>subcutaneous adipose tissue</kwd><kwd>epicardial adipose tissue</kwd><kwd>microRNA-21</kwd><kwd>coronary artery disease</kwd><kwd>coronary artery bypass grafting</kwd><kwd>hyperuricemia</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С.А., Проваторов С.И. Возможности диспансерного наблюдения в снижении смертности от ишемической болезни сердца. Терапевтический архив. 2023;95(1):5–10. DOI: 10.26442/00403660.2023.01.202038</mixed-citation><mixed-citation xml:lang="en">Boytsov S.A., Provatorov S.I. Possibilities of dispensary observation in reducing mortality from coronary heart disease. Therapeutic Archive. 2023;95(1):5–10. (in Russian). DOI: 10.26442/00403660.2023.01.202038</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chow W.S., Tso A.W., Xu A., Yuen M.M. et al. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J. Am. Heart Assoc. 2013;2(1):e004176. DOI: 10.1161/JAHA.112.004176</mixed-citation><mixed-citation xml:lang="en">Chow W.S., Tso A.W., Xu A., Yuen M.M. et al. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J. Am. Heart Assoc. 2013;2(1):e004176. DOI: 10.1161/JAHA.112.004176</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Egbuche O., Biggs M.L., Ix J.H., Kizer J.R. et al. Fatty acid binding protein-4 and risk of cardiovascular disease: the cardiovascular health study. J. Am. Heart Assoc. 2020;9(7):e014070. DOI: 10.1161/JAHA.119.014070</mixed-citation><mixed-citation xml:lang="en">Egbuche O., Biggs M.L., Ix J.H., Kizer J.R. et al. Fatty acid binding protein-4 and risk of cardiovascular disease: the cardiovascular health study. J. Am. Heart Assoc. 2020;9(7):e014070. DOI: 10.1161/JAHA.119.014070</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Huang I.C., Hsu B.G., Chang C.C., Lee C.J. et al. High levels of serum adipocyte fatty acid-binding protein predict cardiovascular events in coronary artery disease patients. Int. J. Med. Sci. 2018;15(12):1268–74. DOI: 10.7150/ijms.25588</mixed-citation><mixed-citation xml:lang="en">Huang I.C., Hsu B.G., Chang C.C., Lee C.J. et al. High levels of serum adipocyte fatty acid-binding protein predict cardiovascular events in coronary artery disease patients. Int. J. Med. Sci. 2018;15(12):1268–74. DOI: 10.7150/ijms.25588</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">von Eynatten M., Breitling L.P., Roos M., Baumann M. et al. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler. Thromb. Vasc. Biol. 2012;32(9):2327–35. DOI: 10.1161/ATVBAHA.112.248609</mixed-citation><mixed-citation xml:lang="en">von Eynatten M., Breitling L.P., Roos M., Baumann M. et al. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler. Thromb. Vasc. Biol. 2012;32(9):2327–35. DOI: 10.1161/ATVBAHA.112.248609</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai H.Y., Wu Y.W., Tseng W.K., Leu H.B. et al. Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions. J. Formos. Med. Assoc. 2021;120(1 Pt3):728–36. DOI: 10.1016/j.jfma.2020.08.007</mixed-citation><mixed-citation xml:lang="en">Tsai H.Y., Wu Y.W., Tseng W.K., Leu H.B. et al. Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions. J. Formos. Med. Assoc. 2021;120(1 Pt3):728–36. DOI: 10.1016/j.jfma.2020.08.007</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Vavassori C., Cipriani E., Colombo G.I. Circulating microRNAs as novel biomarkers in risk assessment and prognosis of coronary artery disease. Eur. Cardiol. 2022;17:e06. DOI: 10.15420/ecr.2021.47</mixed-citation><mixed-citation xml:lang="en">Vavassori C., Cipriani E., Colombo G.I. Circulating microRNAs as novel biomarkers in risk assessment and prognosis of coronary artery disease. Eur. Cardiol. 2022;17:e06. DOI: 10.15420/ecr.2021.47</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Błażejowska E., Urbanowicz T., Gąsecka A., Olasińska-Wiśniewska A. et al. Diagnostic and prognostic value of miRNAs after coronary artery bypass grafting: a review. Biology (Basel). 2021;10(12):1350. DOI: 10.3390/biology10121350</mixed-citation><mixed-citation xml:lang="en">Błażejowska E., Urbanowicz T., Gąsecka A., Olasińska-Wiśniewska A. et al. Diagnostic and prognostic value of miRNAs after coronary artery bypass grafting: a review. Biology (Basel). 2021;10(12):1350. DOI: 10.3390/biology10121350</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yamada H., Suzuki K., Fujii R., Kawado M. et al. Circulating miR21, miR-29a, and miR-126 are associated with premature death risk due to cancer and cardiovascular disease: the JACC Study. Sci. Rep. 2021;11(1):5298. DOI: 10.1038/s41598-021-84707-7</mixed-citation><mixed-citation xml:lang="en">Yamada H., Suzuki K., Fujii R., Kawado M. et al. Circulating miR21, miR-29a, and miR-126 are associated with premature death risk due to cancer and cardiovascular disease: the JACC Study. Sci. Rep. 2021;11(1):5298. DOI: 10.1038/s41598-021-84707-7</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Российское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. DOI: 10.15829/1560-4071-2020-4076</mixed-citation><mixed-citation xml:lang="en">Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for stable coronary artery disease. Russian Journal of  Cardiology. 2020;25(11):4076. (in Russian). DOI: 10.15829/1560-4071-2020-4076</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Российское кардиологическое общество (РКО). Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786</mixed-citation><mixed-citation xml:lang="en">Russian Society of Cardiology (RSC). Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (in Russian). DOI: 10.15829/1560-4071-2020-3-3786</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Мазуров В.И., Мартынов А.И., Гайдукова И.З. и др. «В фокусе гиперурикемия». Резолюция Cовета экспертов. Кардиоваскулярная терапия и профилактика. 2023;22(4):3564. DOI: 10.15829/1728-8800-2023-3564</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Mazurov V.I., Martynov A.I., Gaidukova I.Z. et al. “Focus on hyperuricemia”. The resolution of the Expert Council. Cardiovascular Therapy and Prevention. 2023;22(4):3564. (in Russian). DOI: 10.15829/1728-8800-2023-3564</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Курбанов С.К., Власова Э.Е., Васильев В.П., Галяутдинов Д.М. и др. Прогнозирование течения ишемической болезни сердца у больных с диффузным поражением коронарных артерий после коронарного шунтирования. Российский кардиологический журнал. 2022;27(1):4727. DOI: 10.15829/1560-4071-2022-4727</mixed-citation><mixed-citation xml:lang="en">Kurbanov S.K., Vlasova E.E., Vasiliev V.P., Galyautdinov D.M. et al. Prediction of clinical course in patients with diffuse coronary artery disease after coronary bypass surgery. Russian Journal of Cardiology. 2022;27(1):4727. (in Russian). DOI: 10.15829/1560-4071-2022-4727</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Soltani M.H., Rasti M., Namayandeh S.M., Sarebanhassanabadi M. Short and long-term outcomes of patients with coronary artery bypass surgery. ARYA Atheroscler. 2021;17(5):1–6. DOI: 10.22122/arya.v17i0.2010</mixed-citation><mixed-citation xml:lang="en">Soltani M.H., Rasti M., Namayandeh S.M., Sarebanhassanabadi M. Short and long-term outcomes of patients with coronary artery bypass surgery. ARYA Atheroscler. 2021;17(5):1–6. DOI: 10.22122/arya.v17i0.2010</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pakrad F., Shiri R., Mozayani Monfared A., Mohammadi Saleh R. Predictors of premature mortality following coronary artery bypass grafting: an Iranian single-centre study. Healthcare (Switzerland). 2023;12(1):36. DOI: 10.3390/healthcare12010036</mixed-citation><mixed-citation xml:lang="en">Pakrad F., Shiri R., Mozayani Monfared A., Mohammadi Saleh R. Predictors of premature mortality following coronary artery bypass grafting: an Iranian single-centre study. Healthcare (Switzerland). 2023;12(1):36. DOI: 10.3390/healthcare12010036</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Butt J.H., Sørensen R., Bäck C., Olsen P.S. et al. Short- and longterm cause of death in patients undergoing isolated coronary artery bypass grafting: a nationwide cohort study. J. Thorac. Cardiovasc. Surg. 2018;156(1):54–60.e4. DOI: 10.1016/j.jtcvs.2018.01.106</mixed-citation><mixed-citation xml:lang="en">Butt J.H., Sørensen R., Bäck C., Olsen P.S. et al. Short- and longterm cause of death in patients undergoing isolated coronary artery bypass grafting: a nationwide cohort study. J. Thorac. Cardiovasc. 	Surg. 	2018;156(1):54–60.e4. 	DOI: 	10.1016/j.jtcvs.2018.01.106</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chua T.K.T., Gao F., Chia S.Y., Sin K.Y.K. et al. Long-term mortality after isolated coronary artery bypass grafting and risk factors for mortality. J. Cardiothorac. Surg. 2024;19(1):429. DOI: 10.1186/s13019-024-02943-0</mixed-citation><mixed-citation xml:lang="en">Chua T.K.T., Gao F., Chia S.Y., Sin K.Y.K. et al. Long-term mortality after isolated coronary artery bypass grafting and risk factors for mortality. J. Cardiothorac. Surg. 2024;19(1):429. DOI: 10.1186/s13019-024-02943-0</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X., Xie L., Zhu W., Zhou Y. Association of body mass index and all-cause mortality in patients after cardiac surgery: a dose-response meta-analysis. Nutrition. 2020;72:110696. DOI: 10.1016/j.nut.2019.110696</mixed-citation><mixed-citation xml:lang="en">Liu X., Xie L., Zhu W., Zhou Y. Association of body mass index and all-cause mortality in patients after cardiac surgery: a dose-response meta-analysis. Nutrition. 2020;72:110696. DOI: 10.1016/j.nut.2019.110696</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Takagi H., Umemoto T. Overweight, but not obesity, paradox on mortality following coronary artery bypass grafting. J. Cardiol. 2016;68(3):215–21. DOI: 10.1016/j.jjcc.2015.09.015</mixed-citation><mixed-citation xml:lang="en">Takagi H., Umemoto T. Overweight, but not obesity, paradox on mortality following coronary artery bypass grafting. J. Cardiol. 2016;68(3):215–21. DOI: 10.1016/j.jjcc.2015.09.015</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ardeshiri M., Faritous Z., Haghighi Z.O., Hosseini S. et al. Effect of obesity on mortality and morbidity after coronary artery bypass grafting surgery in Iranian patients. Anesth. Pain Med. 2014;4(2):e18884. DOI: 10.5812/aapm.18884</mixed-citation><mixed-citation xml:lang="en">Ardeshiri M., Faritous Z., Haghighi Z.O., Hosseini S. et al. Effect of obesity on mortality and morbidity after coronary artery bypass grafting surgery in Iranian patients. Anesth. Pain Med. 2014;4(2):e18884. DOI: 10.5812/aapm.18884</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Aittokallio J., Kauko A., Palmu J., Niiranen T. Predictors and outcomes of coronary artery bypass grafting: a systematic and untargeted analysis of more than 120,000 individuals and 1,300 disease traits. J. Cardiothorac. Vasc. Anesth. 2021;35(11):3232–40. DOI: 10.1053/j.jvca.2021.03.039</mixed-citation><mixed-citation xml:lang="en">Aittokallio J., Kauko A., Palmu J., Niiranen T. Predictors and outcomes of coronary artery bypass grafting: a systematic and untargeted analysis of more than 120,000 individuals and 1,300 disease traits. J. Cardiothorac. Vasc. Anesth. 2021;35(11):3232–40. DOI: 10.1053/j.jvca.2021.03.039</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hillis G.S., Cuthbertson B.H., Gibson P.H., McNeilly J.D. et al. Uric acid levels and outcome from coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 2009;138(1):200–5. DOI: 10.1016/j.jtcvs.2008.12.052</mixed-citation><mixed-citation xml:lang="en">Hillis G.S., Cuthbertson B.H., Gibson P.H., McNeilly J.D. et al. Uric acid levels and outcome from coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 2009;138(1):200–5. DOI: 10.1016/j.jtcvs.2008.12.052</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Akashi N., Kuwabara M., Matoba T., Kohro T. et al. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: a nationwide cohort study from Japan. Front. Cardiovasc. Med. 2023;9:1062894. DOI: 10.3389/fcvm.2022.1062894</mixed-citation><mixed-citation xml:lang="en">Akashi N., Kuwabara M., Matoba T., Kohro T. et al. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: a nationwide cohort study from Japan. Front. Cardiovasc. Med. 2023;9:1062894. DOI: 10.3389/fcvm.2022.1062894</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Jansen F., Yang X., Proebsting S., Hoelscher M. et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J. Am. Heart Assoc. 2014;3(6):e001249. DOI: 10.1161/JAHA.114.001249</mixed-citation><mixed-citation xml:lang="en">Jansen F., Yang X., Proebsting S., Hoelscher M. et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J. Am. Heart Assoc. 2014;3(6):e001249. DOI: 10.1161/JAHA.114.001249</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
